Építés alatt – nem éles oldal
Belépés

NCT02361320Toboroz

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 21.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
259 (tervezett)
Első benyújtás
2015. febr. 4.
Kezdés
2015. márc. 9.
Elsődleges befejezés
2028. jún. 27.
Fő szponzor
M.D. Anderson Cancer Center
NCT-szám
NCT02361320

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 259
  • 2015. márc. 9. és az elsődleges befejezés (2028. jún. 27.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • Unstable angina or New York Heart Association grade II or greater congestive heart failure
  • Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
  • Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
  • Patients with an active second malignancy with the exception of non-melanoma skin cancer

Egyéb

  • Presence of distant metastasis
  • Patients whose tumors are defined as resectable
  • Pregnant women with a positive pregnancy test
  • Inability to comply with study and/or follow-up procedures

Kiket keres a vizsgálat

  • PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
  • PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either
    • Unresectable locally advanced disease, defined as primary tumor that involves > 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior mesenteric vein or portal vein, aorta or inferior vena cava invasion, or superior mesenteric vein invasion below the transverse mesocolon
    • Borderline resectable disease, defined as primary tumor that involves =< 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that involves the superior mesenteric vein causing vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction, or primary tumor that abuts or encases (>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)
  • PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
  • PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and to refrain from breast feeding
  • PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer
  • PANCREATIC CANCER: Signed study-specific consent form
  • HEPATOBILIARY CANCER: Diagnosis of
    • Hepatocellular carcinoma: This may be diagnosed in the following ways:
    • Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC)
    • At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
    • Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma
  • HEPATOBILIARY CANCER: Patients may have single or multinodular tumors
  • HEPATOBILIARY CANCER: ECOG PS 0-1
  • HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception
  • HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
  • HEPATOBILIARY CANCER: Patients may be enrolled if:
    • The patient is dispositioned to receive definitive radiotherapy
    • The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy
  • HEPATOBILIARY CANCER: Signed study-specific consent form

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
M D Anderson Cancer CenterHoustonEgyesült ÁllamokToboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.